Microcore has more than two decades of experiences in research, manufacturing and scale up of many Nutrabioceuticals and Theraputicals. Saccharomyces boulardii is a probiotic, non-pathogenic yeast widely used to support gastrointestinal health. It is unique because, unlike bacterial probiotics, it does not colonize the gut permanently and is unaffected by antibiotics, making it especially useful during antibiotic therapy. Clinically, S. boulardii has been shown to help reduce diarrhea, restore healthy intestinal microflora, and alleviate symptoms such as abdominal pain and increased stool frequency. Its long history of safe use and strong clinical evidence makes it a trusted probiotic for both adults and children.

Significances

Clinically proven probiotic yeast with strong evidence from genomic, pre-clinical, and clinical studies supporting safety and efficacy. Helps restore healthy intestinal microflora, especially after infections, antibiotic use, or digestive disturbances. Effective in reducing diarrhea, including antibiotic-associated diarrhea (AAD), travelers diarrhea, and infectious diarrhea. Unaffected by antibiotics because it is a yeast, making it ideal for concurrent use during antibiotic therapy. Supports overall gastrointestinal health by reducing inflammation, improving gut barrier function, and normalizing bowel movements. Non-colonizing and transient, meaning it works while passing through the GI tract without permanently altering gut composition. Safe for adults and children, with over 50 years of global clinical use

• Where MRL 1019 Saccharomyces boulardii is used ?

  

  
  Saccharomyces boulardii is widely used for comprehensive gastrointestinal support, particularly in managing diarrhea, including antibiotic associated, travelers, and acute infectious diarrhea in both adults and children. It effectively helps restore healthy gut flora after antibiotic therapy and serves as supportive care in inflammatory conditions such as IBS and IBD. The probiotic plays an important role in preventing antibiotic-associated side effects by reducing dysbiosis and lowering the risk of Clostridium difficile associated diarrhea. It also strengthens the gut barrier by supporting intestinal integrity, reducing inflammation, and limiting pathogenic bacterial adhesion. In pediatrics, it is well established as a safe option for acute diarrhea, rotavirus-related diarrhea, and microbiota restoration. Additionally, S. boulardii enhances mucosal immunity and modulates gut immune responses. It is included in enteral and clinical nutrition formulas, especially for tube-fed patients to prevent gastrointestinal complications. In general wellness and nutraceutical formulations, it is incorporated for digestive health, immune support, detoxification, and gut brain axis benefits. Beyond human health, it is also used in veterinary applications for digestive support and diarrhea prevention in pets such as dogs, cats, and horses.

• What are the advantages of Specific MRL 1019 Saccharomyces boulardii  ?

  

  
  MRL 1019 Saccharomyces boulardii offers multiple clinical advantages that make it a highly effective and reliable probiotic. It naturally survives harsh gastric conditions, including stomach acid and bile, ensuring high viability as it reaches the intestines. Unlike bacterial probiotics, it is not affected by antibiotics, making it ideal for use during antibiotic therapy. S. boulardii acts rapidly in managing diarrhea and is clinically proven to reduce both its duration and severity across various types. It helps restore gut microbiota balance quickly, particularly after antibiotic use or gastrointestinal infections, and inhibits the adhesion and growth of harmful pathogens such as E. coli, Clostridium difficile, and Salmonella. Its anti-inflammatory properties support intestinal barrier repair, while its ability to enhance secretory IgA production strengthens mucosal immune function. The probiotic is safe for all age groups including adults, children, and the elderly with a long history of global use. It is also highly stable and shelf-resistant compared to many bacterial probiotics, making it suitable for capsules, sachets, and clinical nutrition formulations. As a non-colonizing and transient organism, it does not permanently inhabit the gut but provides strong therapeutic benefits during its passages widely used for comprehensive gastrointestinal support, particularly in managing diarrhea, including antibiotic associated, travelers, and acute infectious diarrhea in both adults and children. It effectively helps restore healthy gut flora after antibiotic therapy and serves as supportive care in inflammatory conditions such as IBS and IBD. The probiotic plays an important role in preventing antibiotic-associated side effects by reducing dysbiosis and lowering the risk of Clostridium difficile associated diarrhea. It also strengthens the gut barrier by supporting intestinal integrity, reducing inflammation, and limiting pathogenic bacterial adhesion. In pediatrics, it is well established as a safe option for acute diarrhea, rotavirus-related diarrhea, and microbiota restoration. Additionally, S. boulardii enhances mucosal immunity and modulates gut immune responses. It is included in enteral and clinical nutrition formulas, especially for tube-fed patients to prevent gastrointestinal complications. In general wellness and nutraceutical formulations, it is incorporated for digestive health, immune support, detoxification, and gut brain axis benefits. Beyond human health, it is also used in veterinary applications for digestive support and diarrhea prevention in pets such as dogs, cats, and horses.

   

  .

• How  the  MRL 1019 Saccharomyces boulardii Mechanism of action ?

  

  Saccharomyces boulardii strengthens the guts immune defense by increasing secretory IgA (sIgA) through activation of immune cells in the Peyers patches, enhancing the gut-associated lymphoid tissue response. The rise in sIg A helps bind and block pathogens and toxins from adhering to the intestinal lining. It also stimulates the production of specific anti-toxin antibodies against harmful bacterial toxins such as Clostridium difficile toxins A and B and E. coli heat-labile toxin, which helps neutralize these toxins and reduce inflammation and fluid loss. Additionally, S. boulardii supports adaptive immunity by promoting the differentiation of B cells into IgA-secreting plasma cells, thereby strengthening targeted immune protection. These combined actions form an immune shield over the intestinal mucosa, reduce pathogen colonization, and enhance the integrity of the gut epithelial barrier.

• When the  MRL 1019 Saccharomyces boulardii will be launched by Microcore ?

  

  
  The developments are at lab scale and expected to complete clinical studies and further launch  by 2028

  
   

•